Drug information
tecovirimat.mp3 |
tecovirimat
Molecular Weight: 376.3325
Expanded access investigational new drug (EA-IND) protocol
The Centers for Disease Control and Prevention (CDC) holds an EA-IND protocol that allows for the use of tecovirimat for the treatment of non-variola orthopoxvirus infections, including mpox. To view the protocol, click on the following link: Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children (Version 6.3; May 5, 2023)
Additionally, please visit the CDC’s Clinical Guidance webpage to access the latest information and updates related to the use of tecovirimat for the treatment of mpox. Recommendations on the use of tecovirimat for preventing and treating mpox in people with HIV are also available from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV and/or the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV.